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Abstract
P-glycoprotein (Pgp; ABCB1/MDR1) is a major efflux transporter at the blood-brain barrier (BBB), restricting the penetration
of various compounds. In other tissues, trafficking of Pgp from subcellular stores to the cell surface has been demonstrated
and may constitute a rapid way of the cell to respond to toxic compounds by functional membrane insertion of the
transporter. It is not known whether drug-induced Pgp trafficking also occurs in brain capillary endothelial cells that form
the BBB. In this study, trafficking of Pgp was investigated in human brain capillary endothelial cells (hCMEC/D3) that were
stably transfected with a doxycycline-inducible MDR1-EGFP fusion plasmid. In the presence of doxycycline, these cells
exhibited a 15-fold increase in Pgp-EGFP fusion protein expression, which was associated with an increased efflux of the
Pgp substrate rhodamine 123 (Rho123). The chemotherapeutic agent mitomycin C (MMC) was used to study drug-induced
trafficking of Pgp. Confocal fluorescence microscopy of single hCMEC/D3-MDR1-EGFP cells revealed that Pgp redistribution
from intracellular pools to the cell surface occurred within 2 h of MMC exposure. Pgp-EGFP exhibited a punctuate pattern at
the cell surface compatible with concentrated regions of the fusion protein in membrane microdomains, i.e., lipid rafts,
which was confirmed by Western blot analysis of biotinylated cell surface proteins in Lubrol-resistant membranes. MMC
exposure also increased the functionality of Pgp as assessed in three functional assays with Pgp substrates (Rho123, eFluxx-
ID Gold, calcein-AM). However, this increase occurred with some delay after the increased Pgp expression and coincided
with the release of Pgp from the Lubrol-resistant membrane complexes. Disrupting rafts by depleting the membrane of
cholesterol increased the functionality of Pgp. Our data present the first direct evidence of drug-induced Pgp trafficking at
the human BBB and indicate that Pgp has to be released from lipid rafts to gain its full functionality.
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Introduction
The transmembrane drug efflux transporter P-glycoprotein
(Pgp; MDR1; ABCB1) contributes to the disposition of a wide
variety of drugs of different therapeutic categories due to its
extensive tissue distribution and broad substrate specificity [1,2].
One of its main functions is to protect tissues against endogenous
and exogenous toxins by extruding such compounds from the cells,
resulting in decreased intracellular drug concentration [3].
Multiple extracellular and intracellular signals regulate the
expression and functionality of Pgp, including transcriptional
modulation via nuclear receptors, like the pregnane-X receptor,
which are involved in drug-induced changes in Pgp expression
[4,5]. In most cells, Pgp is mainly localized in the plasma
membrane, but it is also localized in intracellular compartments,
such as endoplasmic reticulum, Golgi, endosomes and lysosomes,
and cycles between endosomal compartments and the plasma
membrane in a microtubular-actin dependent manner [6].
Modulation of trafficking of Pgp from intracellular reservoirs to
the cell surface alters post-transcriptional Pgp expression, and may
be an effective and rapid way of the cell to respond to potentially
toxic compounds by functional membrane insertion of the efflux
transporter [7].
Intracellular trafficking of Pgp has been demonstrated for
different cell types, particularly liver and cancer cells [6,8–10].
Except for one recent study in rat cerebral microvessel prepara-
tions [11] very little is known about the trafficking mechanisms of
Pgp and their regulation in the brain capillary endothelial cells
that form the blood-brain barrier (BBB). Pgp is an important
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component of this barrier and is expressed mainly on the apical
(luminal) surface of the endothelial cells [5,12]. In the present
study, intracellular trafficking of Pgp was investigated in a human
brain capillary endothelial cell line (hCMEC/D3)[13], using a Pgp
and enhanced green fluorescent fusion protein (Pgp-EGFP)
inducible by doxycycline. To study drug-induced trafficking of
Pgp, we used the chemotherapeutic agent mitomycin C (MMC),
which has previously been shown to increase membrane-associ-
ated Pgp by inducing Pgp trafficking in Madin-Darby canine
kidney (MDCK) and rat hepatoma cells [7].
Methods
Cell culture conditions
Human cerebral microvascular endothelial cells (hCMEC/D3)
were described in detail previously by us [13] and were used for
transfection with a doxycycline-inducible MDR1-EGFP fusion
plasmid as described below. Both wild type and transfected cells
were cultivated in endothelial cell basal medium-2 (EBM-2,
Lonza, Cologne, Germany) supplemented with 5% fetal calf serum
(PAA Laboratories, Co¨lbe, Germany), 1% penicillin (100 U/ml),
streptomycin (100 mg/ml) (Invitrogen, Karlsruhe, Germany),
1.4 mM hydrocortisone (Sigma-Aldrich, Munich, Germany),
5 mg/ml ascorbic acid (Sigma-Aldrich), 1% lipid concentrate
(Invitrogen), 10 mM HEPES (Invitrogen) and 1 ng/ml basic FGF
(Sigma-Aldrich). For induction of Pgp-EGFP expression, 1 mg/ml
doxycycline (Biochrom, Berlin, Germany) was added to the
medium. The dose-dependency of doxcycline’s effect on Pgp
expression and functionality was studied by exposing the cells to
varying concentrations (1 ng/ml, 500 ng/ml, 1 mg/ml) of doxy-
cycline. To control for the effects of doxycycline in the absence of
the expression vector, experiments in wild type cells were
performed with and without doxycycline. Cells (at passages 30–
40) were passaged every 3–4 days on collagen type I- (100 mg/ml)
(Invitrogen) coated 100-mm tissue culture plates (Sarstedt,
Nuembrecht, Germany) maintained at 37uC and 5% CO2.
HEK (human embryonic kidney) 293T cells (DSMZ, Braunsch-
weig, Germany) were cultivated in Dulbecco’s modified Eagle’s
medium containing 4.5 g/l glucose (Sigma-Aldrich), 10% fetal
bovine serum (Invitrogen), 100 U/ml penicillin, 100 mg/ml
streptomycin (Invitrogen) at 37uC and 5% CO2.
Cloning of MDR1-EGFP-pLox
Due to missing compatible restriction sites in the multiple
cloning site (MCS) of the lentiviral expression vector pLOX/TW,
which is under control of a tetracycline-responsive promoter [14],
the MCS of the vector was extended as a first step. Forward and
reverse oligonucleotides were designed containing the sequences of
Spe I and Cla I restriction sites and flanked by Sal I and BamH I
restriction sites. To anneal the oligonucleotides, equal amounts
were mixed, heated to 100uC and cooled down to room
temperature. The annealed oligonucleotides and pLOX/TW
were restriction digested with Sal I and BamH I. The vector was
additionally treated with shrimp alkaline phosphatase (USB,
Cleveland, OH, USA) according to the instructions of the
manufacturer. After ligation of the oligonucleotide into the
pLOX/TW-vector, the vector was electroporated into E. coli
SURE bacteria. Subsequently plasmid preparation of pLOX/
TW/Spe I-Cla I using JETSTAR Plasmid Kits (Genomed, Lo¨hne,
Germany) was performed according to the instructions of the
manufacturer and the integrity of the construct was confirmed by
sequencing using the ABI Prism 310 capillary sequencer (BigDye
Terminator Cycle Sequencing Ready Reaction Mix v. 1.1;
Applied Biosystems, Darmstadt, Germany). In a second step
MDR1-EGFP was cloned into the lentiviral expression vector
pLOX/TW/Spe I-Cla I. To do so, a PCR product containing a
MDR1-EGFP fusion construct flanked by Spe I and Cla I
restriction sites was generated using a MDR1-linker-EGFP vector
(with EGFP placed at the C terminus of MDR1) kindly provided
by Piet Borst (The Netherlands Cancer Institute, Amsterdam, The
Netherlands) as template. Forward primer (59-GCA GAC TAG
TGC CAC CAT GGA TCT TGA AGG GGA CCG C-39)
comprised a Spe I restriction site and reverse primer (59-GCT
CAT CGA TTT ACT TGT ACA GCT CGT CCA TGC C-39) a
Cla I restriction site (underlined). PCR was performed at 55uC
using Pfu Ultra DNA polymerase (Stratagene, LaJolla, CA, USA)
according to the instructions of the manufacturer.
After purification (GeneJETTM Gel Extraction Kit; Fermentas,
St. Leon-Rot, Germany) the PCR product was restriction digested
and ligated into the lentiviral expression vector pLOX/TW/Spe I-
Cla I. Amplification of the cloned construct was carried out by
electrotransformation into competent E. coli SURE bacteria
followed by plasmid preparation using JETSTAR Plasmid Kits
(Genomed) according to the instructions of the manufacturer. The
integrity of the cloned construct was confirmed by sequencing
using the ABI Prism 310 capillary sequencer (BigDye Terminator
Cycle Sequencing Ready Reaction Mix v. 1.1; Applied Biosys-
tems).
Lentivirus production
HEK 293T cells (16107 cells) were seeded in a 145 cm2 petri
dish coated with poly-L-lysine and cultivated overnight. Trans-
fection was accomplished by using calcium-phosphate transfection
and either 50 mg pUCL-MIK (tetracycline-dependent transacti-
vator) or 50 mg MDR1-EGFP-pLOX plus 12.5 mg pMD.G VSV-
G and 50 mg pCMVDR8.2. Twenty-four hours after transfection,
medium was removed and fresh medium containing 10 mM
HEPES and 10 mM sodium butyrate was added to the cells.
Lentivirus-containing supernatants were harvested and filtered
48 hours after transfection.
Generation of lentivirally modified hCMEC/D3 cells
26104 hCMEC/D3 cells were seeded in one well of a 6-well
plate. For lentiviral infection of cells, virus containing supernatants
(115.4 ml MIK-virus +173.1 ml MDR1-EGFP virus) were diluted
in medium to a total volume of 1.2 ml with a final concentration of
8 mg/ml polybrene (Sequabrene, Sigma). Medium was removed
from cells and the infection mixtures containing the viruses were
added. 24 h after infection, gene expression was induced by
adding 1 mg/ml doxycycline (Biochrom) in fresh medium.
Fluorescence activated cell sorting
EGFP-positive hCMEC/D3-MDR1-EGFP cells were collected
by fluorescence-activated cell sorting with a FACS Aria IIu
(Becton Dickinson, CA, USA). Dead cells were excluded by using
scatter parameters and cell aggregates were excluded by using
pulse width.
Western blot analysis
Human brain endothelial cells (hCMEC/D3, hCMEC/D3-
MDR1-EGFP) were lysed in buffer containing 25 mM Tris-HCl,
pH 8, 50 mM NaCl, 0.5% (w/v) sodium deoxycholate (DOC),
and 0.5% (w/v) Triton X-100 and supplemented with complete
protease inhibitor (Roche, Mannheim, Germany). Disruption of
cell lysates was performed by drawing up the cell suspension
twenty times into a syringe with a small gauge needle (21G) on ice.
Protein concentrations in the lysates were determined by using the
Trafficking of P-Glycoprotein
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Pierce BCA Protein Assay kit (Thermo Scientific, Bonn, Germany)
according to the manufacturer’s instructions. Equal amounts of
total protein were separated on 10% SDS-PAGE gels and
transferred to PVDF membranes which were blocked overnight
in 5% milk in phosphate buffered saline supplemented with
Tween-20 (PBST: 137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4, 1.4 mM KH2PO4, pH 7.3, 0.05% (w/v) Tween-20)
at 4uC. Membranes were incubated with primary antibodies anti-
PGP 1:200 (Signet Laboratories, Dedham, MA, USA) and anti-
Actin 1:100 (Sigma-Aldrich) for 1 h in 2% milk in PBST at room
temperature (RT) and washed three times for 10 min in PBS-T.
Secondary antibodies anti-mouse-HRP 1:1000 and anti-rabbit-
HRP 1:1000 (Dako, Hamburg, Germany) were incubated for 1 h
in 2% milk in PBST at RT and washed three times for 10 min in
PBST. Proteins were detected by enhanced chemiluminescence
using SuperSignal West Femto Chemiluminescent Substrate
(Thermo Scientific) and the ChemiDoc system (Bio-Rad, Munich,
Germany) with QuantityOne software (Bio-Rad) according to the
manufacturer’s protocol. Relative protein expressions were quan-
tified densitometrically with QuantityOne (Bio-Rad) software and
calculated by normalization to the reference signals of actin with
GraphPad Prism software (GraphPad, San Diego, CA, USA). For
quantification of Pgp expression at the cell surface, Pgp signals
were normalized relative to the Coomassie-stained portion of the
gel.
Treatment with mitomycin C
Four days after reaching confluence, cells were stimulated with
non-cytotoxic concentrations of MMC (0.1 mM, 1 mM, 10 mM,
50 mM and 100 mM) (Sigma-Aldrich) in Opti-MEM (Invitrogen)
at 37uC and 5% CO2. If not otherwise indicated, cells were
exposed to MMC for 4 h, which was based on previous
experiments by Maitra et al. [7] with MDCK and rat hepatoma
H4II cells. The effects of MMC exposure were either determined
directly after termination of exposure (i.e., at 4 h) or 20 h later,
i.e., 24 h after onset of MMC treatment. Control cells were treated
only with Opti-MEM (Invitrogen). For 24 hour experiments,
Opti-MEM was removed after 4 hours of MMC or control
exposure, and cells were treated with fresh culture medium. In
preliminary experiments, we also tested the effects of 24 h
exposure to MMC (not shown), but since effects were similar to
those obtained with 4 h of exposure, all subsequent experiments
were performed with the shorter exposure duration.
Confocal fluorescence microscopic analysis of living cells
hCMEC/D3-MDR1-EGFP cells were plated on collagen type I
(100 mg/ml; Invitrogen)-coated 100-mm tissue culture plates
(Sarstedt) containing a 42-mm glass plate (H. Sauer Laborbedarf,
Reutlingen, Germany). Four days after reaching confluence cells
were pretreated with MMC (1 mM) for either 1 or 3 h in Opti-
MEM (Invitrogen) at 37uC and 5% CO2. Cells were stained for
0.5 h with 5 mM bisbenzimide H (Sigma-Aldrich) in Opti-MEM
(Invitrogen) at 37uC and 5% CO2. For confocal fluorescence
microscopy glass plates with cells were fitted into a PeCon open
chamber (PeCon, Erbach, Germany) and MMC (1 mM) in Opti-
MEM without phenol red (Invitrogen) was added. Fluorescence
images were taken every 3.6 min for the next hour using a Leica
SP5 confocal fluorescence microscope with a 636water objective
(Leica Microsystems, Bensheim, Germany) in a climate box
(PeCon) at 37uC. Excitation wavelengths of 405 nm (bisbenzimide
H) or 481 nm (Pgp-EGFP) were used.
Cell surface biotinylation and isolation of Lubrol-resistant
membranes
hCMEC/D3-MDR1-EGFP cells were plated on collagen type I
(100 mg/ml) (Invitrogen) coated 100-mm tissue culture plates
(Sarstedt). Four days after reaching confluence the cell surface
proteins were isolated. Cells were washed twice with ice- cold PBS
and incubated with 10 ml 0.25 mg/ml EZ-Link Sulfo-NHS-SS-
Biotin (Thermo Scientific) in PBS for 30 min gently shaking on
ice. The reaction was stopped by adding 500 ml Tris (50 mM final
concentration, pH 8). Cells were scraped off and collected in
50 ml tubes and centrifuged at 5006g for 5 min at 4uC. The cell
pellets were washed with 5 ml Tris-buffered saline (TBS; 25 mM
Tris, 0.15 M sodium chloride, pH 7.2) and centrifuged at 5006g
for 5 min. After discarding the supernatants, cell pellets were
resuspended in lysis buffer (25 mM Tris-HCl, 50 mM NaCl, 0.5%
(w/v) DOC and 0.5% (w/v) Triton X-100) supplemented with
complete protease inhibitor (Roche). Cell lysates were disrupted by
passing the cell suspension twenty times through a syringe with a
small gauge needle (21G) and incubated 30 minutes on ice.
Samples were centrifuged at 10,0006g for 2 min and the clarified
supernatants were mixed with 100 ml Neutravidin Agarose beads
(Thermo Scientific) for 1 h with shaking at RT. Thereafter, the
beads were washed two times with PBS, 0.5% (w/v) Triton X-100
and 0.05% (w/v) DOC and twice with 500 mM NaCl, 125 mM
Tris, 10 mM EDTA and 0.5% (w/v) Triton X-100 (pH 8). Cell
surface proteins were eluted from the Neutravidin beads with
SDS-PAGE sample buffer under reducing conditions (62.5 mM
Tris-HCl, pH 6.8, 1% SDS, 10% (w/v) glycerol and 50 mM
dithiothreitol for 1 h with shaking at RT. The eluates were
centrifuged for 2 min at 1,0006g and the proteins were analysed
by Western blotting as described above. In some experiments
Lubrol-detergent extraction of the biotinylated cells was per-
formed by adding 1% (w/v) of Lubrol WX in PBS, and the
clarified detergent extracts were centrifuged at 100,0006 g for
45 min at 4uC (Beckman Optima LE-80, SW-55Ti rotor). Lubrol-
resistant membranes (DRMs) retained in the pellet were
resuspended in PBS containing 0.5% (w/v) DOC and 0.5% (w/
v) Triton X-100 and the protease inhibitor cocktail. Treatment of
the resuspended DRMs as well as the supernatants with
Neutravidin-Agarose beads and analysis by Western blotting were
performed as described above.
Rhodamine 123 uptake assay
Uptake assays with the cell-permeant, cationic, green-fluores-
cent Pgp substrate rhodamine 123 (Rho123; Sigma-Aldrich) were
performed to evaluate Pgp transport function [13,15,16]. In our
hands this assay was more sensitive and less variable to determine
drug-induced alterations in Pgp functionality than several other
uptake assays with Pgp substrates, including vinblastine and
digoxin, which we previously used [17]. For the Rho123 uptake
assay, cells were grown on collagen type I (100 mg/ml) (Invitrogen)
coated 6-well plates (Greiner, Frickenhausen, Germany). Four
days after reaching confluence cells were stimulated with MMC as
described above. At different times after MMC exposure, the cells
were incubated with 10 mM Rho123 (Sigma-Aldrich) in Opti-
MEM (Invitrogen) shaking for 1 h at 37uC and 5% CO2. Cells
were washed twice with PBS and scraped in 500 ml ice cold PBS
and collected in 1.5 ml tubes, which were centrifuged eight
minutes at 3006 g at 4uC. The cell pellet was resuspended in
200 ml lysis buffer (25 mM Tris-HCl, 50 mM NaCl, 0.5% (w/v)
DOC and 0.5% (w/v) Triton X-100). Protein determination and
Western blots were performed as described above. Fluorescence
was measured with the FLUOstar OPTIMA (BMG Labtech,
Ortenberg, Germany) and was calculated as absolute fluorescence
Trafficking of P-Glycoprotein
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in the cell lysate per mg of protein. The extent of Rho123 uptake
varied between different cell preparations, so that concurrent
controls were used in all experiments.
In some experiments, the Pgp inhibitor tariquidar (0.5 mM) was
added to the cells 1 h before Rho123 and during the 1 h of
incubation with Rho123 in order to determine whether the
alterations in Rho123 uptake induced by transfection with Pgp-
EGFP or exposure to MMC could be counteracted by inhibition
of Pgp.
Rhodamine 123 efflux assay
For using the Rho 123 assay in the efflux configuration [18],
cells were preloaded with 10 mM Rho123 (Sigma Aldrich) in Opti-
MEM (Invitrogen) for 15 min on ice. After cells were washed twice
in PBS and medium was changed to Opti-MEM (Invitrogen)
without Rho123, the cells were placed in the incubator (37uC and
5% CO2) and the decay of intracellular florescence was measured
after 15, 30 and 60 min in the absence or presence of the Pgp
inhibitor tariquidar (0.5 mM). To control Rho123 preloading, cells
were directly harvested after preincubation. Fluorescence was
measured as described above and was calculated as fluorescence
efflux per min.
eFluxx-ID Gold uptake assay
To confirm the findings of the Rho123 assay with a second
method, we used the fluorescent probe eFluxx-ID Gold, a recently
presented xanthene-based small molecule dye that, in combination
with a Pgp inhibitor, can be used to monitor Pgp functionality in
live cells [19,20]. hCMEC/D3-MDR1-EGFP (doxycycline-on)
cells were trypsinized and incubated for 30 min at 37uC in phenol
red free Opti-MEM medium (Invitrogen) with eFluxx-ID Gold
(ENZO Life Sciences, Lo¨rrach, Germany) according to the
manufacturer’s protocol. Cells were analyzed by flow cytometry
(FACSCanto; BD Biosciences, Heidelberg, Germany). Each flow
cytometry analysis consisted of a record of 100,000 cells. The
uptake of eFluxx-ID Gold of EGFP-positive cells was measured in
the FL2 (PE) and FL1 (FITC) channel. Dead cells were excluded
by using scatter parameters. In parallel experiments, tariquidar
(0.5 mM) was added to the cells 1 h before eFluxx-ID Gold and
during the incubation with eFluxx-ID Gold in order to determine
whether the alterations in eFluxx-ID Gold uptake induced by
transfection with Pgp-EGFP or exposure to MMC could be
counteracted by inhibition of Pgp.
Calcein-AM extrusion assay
To confirm the findings of the uptake assays (Rho123 and
eFluxx-ID Gold) with a third method, we performed the calcein-
AM extrusion assay [21]. The lipophilic nonfluorescent acetox-
ymethyl (AM) ester of calcein diffuses into cells where it is
hydrolyzed to calcein, a fluorescent organic anion. Because
calcein-AM is effluxed by Pgp, the intracelluar accumulation of
calcein is measured as an indirect (and inverse) measure of calcein
AM efflux [21]. For the present experiments, we performed the
assay as described by Bauer et al. [22]. Following exposure to
MMC, hCMEC/D3-MDR1-EGFP (doxycycline-on) cells were
washed two times with PBS and were subsequently incubated with
2 mM calcein-AM (Sigma-Aldrich) for 15 min at 37uC. Cells were
harvested and further analysed as described in Rho123 uptake
assay section. In further experiments for calcein-AM kinetic
studies, which were performed essentially as described by Bauer et
al. [22], cells were seeded on 96-well plates. Cells were preloaded
with calcein-AM (0.25 mM, 0.5 mM, 1 mM or 2 mM) and
transferred into a FLX 800 microplate reader (Bio Tek, Bad
Friedrichshall, Germany) for 1 h at 37uC where fluorescence was
measured every 30 seconds and was calculated as absolute
fluorescence per second per mg of protein. In parallel experiments,
tariquidar (0.5 mM) was added to the cells 1 h before calcein-AM
and during the incubation with calcein-AM in order to determine
whether the alterations in calcein accumulation induced by
transfection with Pgp-EGFP or exposure to MMC could be
counteracted by inhibition of Pgp.
Treatment with cyclodextrin
For depletion of cell membrane cholesterol, methyl-b-cyclodex-
trin (MbCD, Sigma-Aldrich) was used [23]. MbCD (Sigma-
Aldrich) was dissolved in Opti-MEM medium (Invitrogen) at a
final concentration of 10 mM. hCMEC/D3-MDR1-EGFP cells
were treated for two hours with 10 mM MbCD. Cells were
washed twice with PBS and rhodamine 123 uptake assays were
performed as described above.
Flow cytometric analysis
hCMEC/D3 wild type, hCMEC/D3-MDR1-EGFP (doxycy-
cline-on) and hCMEC/D3-MDR1-EGFP (doxycycline-off) cells
were trypsinized and flow cytometric analysis were performed on a
FACSCanto (BD Biosciences) using forward (FSC) and side (SSC)
scattering parameters.
Statistics
Drug effects were compared with individual controls, using
either Student’s t-test or, when data were not normally distributed,
the U-test of Mann and Whitney, using PRISM 5 software
(GraphPad Software Inc., La Jolla, CA, USA). For analysis of
differences between several groups in the same experiment,
analysis of variance (ANOVA) followed by Dunnett’s or
Bonferroni’s Multiple Comparison Tests were used. Tests used
were two-sided and a P,0.05 was considered significant.
Results
Generation of conditional doxycycline-dependent Pgp-
EGFP expressing hCMEC/D3-MDR1-EGFP cells
To investigate Pgp trafficking, we generated conditional
doxycycline-dependent Pgp-EGFP expressing hCMEC/D3-
MDR1-EGFP cells with a lentiviral expression system. As a
template for cloning MDR1-EGFP in the lentiviral expression
vector (pLOX/TW/Spe I-Cla I) we used a MDR1-linker-EGFP
construct that was previously generated by Piet Borst (see
experimental procedures) and, to our knowledge, has never been
used before in any published study. In the MDR1 sequence of this
construct we identified three of the most common single nucleotide
polymorphisms, T1236C (Gly412Gly), T2677G (Ser893Ala) and
T3435C (Ile1145Ile), which have been described in MDR1 of
humans [24]. To produce MDR1-EGFP-containing lentiviral
particles, HEK293T cells were transfected with MDR1-EGFP-
pLOX/TW/Spe I-Cla I, pMD.G VSV-G and pCMVDR8.2.
These lentiviral particles were then used to infect hCMEC/D3-
cells. Doxycycline-dependent expression of MDR1-EGFP was
mediated by coinfection of hCMEC/D3 cells with MIK-lentivirus
encoding the tet-transactivator. The successful infection was
detected by EGFP fluorescence and Western blot analysis of the
Pgp-EGFP fusion protein (data not shown). Subsequently, EGFP
positive hCMEC/D3 cells (6.4%) were isolated by fluorescence-
activated cell sorting.
Trafficking of P-Glycoprotein
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Characterization of conditional doxycycline-dependent
Pgp-EGFP expressing hCMEC/D3-MDR1-EGFP cells
Confocal fluorescence microscopic analysis of sorted hCMEC/
D3-MDR1-EGFP (doxycycline-on) cells revealed a predominant
intracellular localization of the Pgp-EGFP fusion protein
(Figure 1A). hCMEC/D3-MDR1-EGFP cells are therefore well
suited to analyse membrane-associated trafficking from intracel-
lular pools. The phenotype (size, granularity, vitality) of the
transfected cells (with or without doxycycline) did not differ from
wild type when analyzed by flow cytometry (Figure 1B). To assess
functionality of Pgp-EGFP inducible doxycycline-on/-off-system
we compared Pgp expression of non-induced Pgp-EGFP (doxycy-
cline-off) and induced Pgp-EGFP (doxycycline-on) hCMEC/D3-
MDR1-EGFP cells versus hCMEC/D3 wild type cells by Western
blot analysis (Figure 1C). hCMEC/D3 wild type cells expressed a
170-kDa protein band corresponding to endogenous Pgp whereas
non-induced hCMEC/D3-MDR1-EGFP cells expressed an ap-
proximately 200-kDa protein band corresponding to the predicted
size of the chimeric MDR1-EGFP (Figure 1C). In the induced
cells, the 200 kDa band was too intense to visualize any
endogenous Pgp. When normalized to actin, the expression level
of Pgp in hCMEC/D3 wild type cells did not differ significantly
from that of the Pgp-EGFP fusion protein in hCMEC/D3-
MDR1-EGFP (doxycycline-off) cells (Figure 1D). Furthermore, the
functionality assessed by efflux of Rho123 was very similar
(Figure 1E). In the presence of doxycycline, hCMEC/D3-MDR1-
EGFP cells exhibited an about 15-fold increase in Pgp-EGFP
fusion protein expression (Figure 1D) and significantly decreased
Rho123 accumulation in comparison to non-induced hCMEC/
D3-MDR1-EGFP (Figure 1E). Compared to hCMEC/D3-
MDR1-EGFP without doxycycline, the decrease in Rho123
accumulation in doxycycline-induced hCMEC/D3-MDR1-EGFP
cells was only 24.1% on average (Figure 1E), substantiating the
findings from confocal fluorescence microscopic analysis of these
cells (Figure 1A) that most of the Pgp-EGFP fusion protein was
localized intracellularly and thus not functionally expressed at the
cell membrane. We repeated the experiment illustrated in
Figure 1E several times (for example see Figure S1) and always
determined a significant decrease in Rho123 accumulation in the
doxycycline-induced cells, but the extent of this decrease varied
between different cell preparations between 24.1 and 72.0%
(mean 46.2%; 5 experiments with 3 samples per experiment).
In addition to performing the Rho123 assay as an accumulation
assay as shown in Figure 1E, we also used an efflux configuration
with preloading the cells with Rho123 at 4uC and then measuring
the decay of intracellular fluorescence at 37uC, thus determining
efflux rates in the presence and absence of tariquidar (Figure S2).
This assay demonstrated the enormous efflux capacity of the
doxycycline-induced hCMEC/D3-MDR1-EGFP cells. Pgp inhi-
bition by tariquidar significantly reduced the Rho123 efflux, but
inhibition was only partial under these conditions (Figure S2),
which may indicate that either the concentration of tariquidar
used (0.5 mM) was not sufficient to completely block the Pgp-
mediated efflux of Rho123 or that other transporters were
involved in this efflux.
To study the dose-dependence of induction of Pgp expression
and functionality by doxycycline, hCMEC/D3-MDR1-EGFP
cells were exposed to different concentrations of doxycyline,
ranging from 1 ng/ml to 1 mg/ml. Doxycycline dose-dependently
increased both Pgp expression and its functionality (as measured
by the Rho123 assay) over this concentration range (Figure S1). In
all subsequent experiments, a concentration of 1 mg/ml was used,
because this resulted in the most intense labeling of the Pgp-EGFP
fusion protein in confocal fluorescence microscopic analysis of
hCMEC/D3-MDR1-EGFP cells.
Exposure of wild type cells to doxycycline did not induce the
expression or functionality of Pgp (Figure 2A). In doxycycline-
induced hCMEC/D3-MDR1-EGFP cells, the Pgp inhibitor
tariquidar counteracted the increased efflux of Rho123 in both
versions of this assay (Figure S2 and Figure 2B). In addition to
Rho123, we also used the eFluxx-ID Gold and calcein-AM assays
to demonstrate functionality of Pgp in the MDR1-EGFP
transfected cells (Figure 2C,D). In all assays, tariquidar signifi-
cantly counteracted the efflux of the Pgp substrates
(Figure 2B,C,D).
In the calcein AM extrusion assay, we also determined the
transport rate of calcein AM efflux (by measuring intracellular
calcein) in doxycycline-induced hCMEC/D3-MDR1-EGFP cells
at different concentrations of the Pgp substrate (Figure S3).
Average transport rate (in fluorescence of intracellular calcein per
sec per mg protein) linearily increased with increasing concentra-
tions of calcein AM and was 3.9 at 0.25 mM calcein AM, 7.2
(0.5 mM), 15.0 (1 mM), and 37.0 (2 mM), respectively (r = 0.9904;
P= 0.0048 when analyzed by linear regression analysis). Transport
was inhibited by tariquidar at all concentrations of calcein AM in
this assay (Figure S3).
Mitomycin C-induced trafficking of Pgp-EGFP fusion
protein
As summarized in Figure 3, three experimental strategies were
used to determine whether MMC exposure induces Pgp trafficking
from intracellular compartments to the plasma membrane in
human brain endothelial cells, hCMEC/D3-MDR1-EGFP (doxy-
cycline-off and doxycycline-on), and whether this trafficking
increases the functionality of the transporter.
Confocal fluorescence microscopic analysis of Pgp
trafficking
First, we used confocal fluorescence microscopic analysis of
single living human endothelial cells to follow the trafficking of the
Pgp-EGFP chimeras (Figure 4). When cells were exposed for 4 h
to MMC and observed by confocal microscopy in the last hour of
the exposure period, no changes in the intracellular localization of
Pgp-EGFP could be detected (not shown). To examine the
possibility that this is due to a rapid trafficking of Pgp-EGFP after
administration of MMC and does not reflect an intracellular block
of the chimeric protein, we shortened MMC treatment to 2 h and
observed the cells during the second hour of exposure (Figure 3A).
Under these conditions, the MDR1-EGFP fusion protein
trafficked from intracellular pools to the cell surface (Figure 4
and Movie S1). The first detectable trafficking event required
approximately 15 min. Following a halt of Pgp membrane
trafficking of approximately 20 minutes, a second trafficking event
could be observed. This required approximately 50 minutes in
which Pgp-EGFP became distributed at the cell surface mem-
brane. Strikingly, Pgp-EGFP exhibited a punctuate pattern at the
cell surface compatible with concentrated regions of the fusion
protein in particular membrane patches, presumably membrane
microdomains (Figure 4 and Movie S1). When using the same
time frame in untreated control cells, we only observed
intracellular trafficking, but no trafficking to the cell membrane
as observed with MMC (Movie S2). During the preparation of our
manuscript, Huber et al. [20] demonstrated by using spectral
position determination microscopy (SPDM) that Pgp clusters in
the membrane of hCMEC/D3 cells, thus supporting our findings.
Nevertheless, trafficking of Pgp was not addressed in their study.
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Western blot analyses of Pgp trafficking
Next, we wanted to corroborate biochemically our findings of a
cell surface expression of Pgp-EGFP after MMC treatment by
Western blot analyses. As shown in Figure 5A, Pgp-EGFP fusion
protein was significantly increased at the plasma membrane upon
MMC treatment, whereas the total amount of Pgp-EGFP fusion
protein was not significantly changed in whole cell lysates of MMC
treated hCMEC/D3-MDR1-EGFP cells (Figure 5C,D). Following
2 h of MMC (1 mM) exposure, the expression level of Pgp-EGFP
fusion protein at the plasma membrane increased by approxi-
mately 50% at the end of exposure (Figure 5B). Twenty h after a 4-
h exposure with MMC, the average increase reached 80%
(Figure 5B).
Functional analysis of Pgp trafficking by the rhodamine
123 assay
In order to determine whether the MMC-induced trafficking of
the Pgp-EGFP fusion protein increased Pgp-mediated drug efflux,
the efflux of the Pgp substrate Rho123 was studied, under both
doxycycline-off and –on conditions (Figure 3C). As shown in
Figure 6A, a significant decrease in Rho123 accumulation was
observed in hCMEC/D3 (doxycycline-off) cells stimulated with
MMC (0.1 mM, 1 mM, 10 mM, 50 mM and 100 mM), when the
experiment was performed 20 h after 4 h MMC exposure, thus
demonstrating that MMC increased the functionality of Pgp. The
maximum effect of MMC (,50% vs. control) was determined at
concentrations of 10-100 mM MMC. In doxycycline-induced
hCMEC/D3-MDR1-EGFP cells, rhodamine accumulation was
significantly decreased (by 37%) already in the absence of MMC,
which was further enhanced by MMC at concentrations of 1-
100 mM (Figure 6A). The maximum effect (238% vs. control) was
observed at concentrations of 10–100 mM MMC. Overall, the
doxycycline-induced cells seemed to be less sensitive to MMC than
the non-induced cells (but see Figure 2). When the experiment
with 1 mM MMC was repeated several times in doxycycline-
induced hCMEC/D3-MDR1-EGFP cells, the effect size of the
decrease in Rho123 uptake 20 h after 4 h of MMC exposure was
quite consistent with 222% (Figure 2B), 223.7% (Figure 6A) and
224.4% (Figure 6B), respectively. However, such an effect was not
observed at earlier time points following MMC exposure
(Figure 6B), indicating a temporal disconnect between the Pgp
trafficking and the time to reach measurable alterations in Pgp
function.
Figure 1. Conditional doxycycline-dependent Pgp-EGFP-expressing hCMEC/D3-MDR1-EGFP cells. (A) Representative images showing
intracellular localization of Pgp-EGFP fusion protein in hCMEC/D3-MDR1-EGFP (doxycycline-on) cells. Cell nuclei of living cells were stained with
bisbenzimide H (blue) (scale bar = 30 mm). (B) Flow cytometric analysis of relative cell size and granularity of hCMEC/D3 wild type, hCMEC/D3-MDR1-
EGFP (doxycycline-on) and hCMEC/D3-MDR1-EGFP (doxycycline-off) cells, indicating the lack of any obvious differences between the three
conditions; furthermore, as indicated by comparable extent of cell debris, the vitality of the cells does not differ. Along the X-axis is the FSC(Forward
SCatter) parameter, while the Y-axis shows the SSC(Side SCatter) parameter. (C,D) Significant Pgp-EGFP fusion protein induction in hCMEC/D3-MDR1-
EGFP cells by doxycycline (1 mg/ml) was analyzed by Western blot. Control whole cell lysates of hCMEC/D3 wild type (Wt) and hCMEC/D3-MDR1-EGFP
(doxycycline-off/on) cells were used. In C, one representative Western blot of three is shown. Bands were analysed densitometrically and Pgp signals
were normalized on actin (D). (E) Induction of Pgp-EGFP by doxycycline (1 mg/ml) significantly decreases Rho123 accumulation in hCMEC/D3-MDR1-
EGFP cells confirming that Pgp-EGFP fusion protein is functional. Data in (D) and (E) are shown as mean6 SEM of three experiments. Asterisks denote
values that were significantly different from corresponding controls (P,0.05). In all experiments with wild type cells, doxycycline was added for
control in order to exclude that doxycycline induces Pgp expression and function also in the absence of an expression vector (see also Figure 2A).
doi:10.1371/journal.pone.0088154.g001
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The increased efflux of Rho123 in response to MMC exposure
was significantly reduced by tariquidar under both doxycycline-off
and –on conditions (Figure 2B). However, as shown in Figure 2B,
tariquidar did not completely counteract the effect of MMC,
which may indicate a non-specific effect of MMC on Rho123
distribution. We therefore used two additional assays (eFluxx-ID,
calcein AM) to study the effects of MMC on Pgp functionality.
Functional analysis of Pgp trafficking by the eFluxx-ID
Gold assay
The eFluxx-ID Gold assay was performed to analyze MMC
dependent Pgp activity of only viable and EGFP-positive cells
(Figure 2C). Intracellular accumulation of eFluxx-ID Gold was
significantly reduced by 46% upon MMC treatment (1 mM) of
hCMEC/D3-MDR1-EGFP cells under doxycycline-on conditions
(Figure 2C). In the presence of tariquidar, the Pgp activity of
Figure 2. Effects of the Pgp inhibitor tariquidar (TQ; 0.5 mM) in three functional assays, in which alterations in Pgp efflux are
indirectly measured by determining intracellular concentrations of Pgp substrates (Rho123, eFluxx-ID Gold) or their metabolite
(calcein AM). Data are shown as mean6 SEM of three experiments; all experiments with one uptake assay were performed together to avoid inter-
experiment variation. In experiments with mitomycin C (MMC) (B,C,D), experiments were performed 20 h after a 4-h exposure to 1 mM MMC.
Significant differences between treatments are indicated by asterisk (P,0.01) except for D, in which significance level of the effect of MMC was
P = 0.0188 (indicated by rhomb). (A) shows data from the Rho123 uptake assay in nontransfected (wild type) hCMEC/D3 cells in the absence or
presence of doxycycline (Dox). Doxycycline (1 mg/ml) did not alter the functionality of Pgp. Tariquidar significantly increased the uptake of Rho123 in
wild type cells both in the absence and presence of doxycycline to the same extent. Much higher concentrations (100 mg/ml) of doxycycline have
been shown to increase Pgp expression and functionality in MCF-7 breast carcinoma cells [37]. (B) shows data from the Rho123 uptake assay in
transfected hCMEC/D3-MDR1-EGFP cells in the absence and presence of doxycycline. In the absence of doxycycline (open columns), tariquidar
significantly increased Rho123 accumulation (i.e., decreased Rho123 efflux) by only about 15%. In the presence of doxycycline, accumulation of
Rho123 was only about 50% of that under doxycycline-off conditions, which was completely counteracted by tariquidar. When experiments were
performed 20 h after a 4-h exposure to 1 mM MMC, Rho123 accumulation was significantly reduced by 15% under doxycycline-off and 22% under
doxycycline-on conditions. Tariquidar counteracted the enhanced functionality of Pgp in response to MMC exposure. However, the tariquidar-
induced increase in Rho123 accumulation in MMC-exposed cells remained significantly below the increase seen in the absence of MMC, which was
seen both under doxycycline-on and -off conditions. (C) shows data from intracellular accumulation of eFluxx-ID Gold in transfected hCMEC/D3-
MDR1-EGFP cells in the presence of doxycycline. In this assay, by using scatter parameters and FL1 (FITC) channel, only viable and EGFP-positive cells
were analyzed for intracellular accumulation of the fluorescent Pgp probe. Following MMC exposure, eFluxx-ID Gold accumulation was significantly
reduced by 46% under doxycycline-on conditions. Tariquidar completely counteracted the enhanced functionality of Pgp in response to MMC
exposure. (D) shows data from intracellular accumulation of calcein in transfected hCMEC/D3-MDR1-EGFP cells in the presence of doxycycline.
Following MMC exposure, calcein accumulation was significantly reduced by 10% under doxycycline-on conditions. Tariquidar completely
counteracted the enhanced functionality of Pgp in response to MMC exposure.
doi:10.1371/journal.pone.0088154.g002
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MMC treated cells was completely antagonized in comparison to
untreated cells (Figure 2C), thus arguing against any non-specific
effects of MMC as indicated by the Rho123 data shown in
Figure 2B. Instead, when comparing the MMC data from the
Rho123 and eFluxx-ID Gold assays, the Rho123 assay seemed to
underestimate the effect of MMC on Pgp functionality. To further
examine whether the data on the temporal effects of MMC
exposure on Pgp functionality obtained with the Rho123 assay
(Figure 6B) correctly indicated a temporal disconnect between Pgp
trafficking and the time to reach measurable alterations in Pgp
function, these experiments were repeated with the eFluxx-ID
Gold assay. As shown in Figure 7, this experiment confirmed the
data with the Rho123 assay that a significant increase in Pgp
functionality was only observed 24 h after onset of a 4 h MMC
exposure. Again, tariquidar completely counteracted the MMC-
induced increase in Pgp functionality in the eFluxx-ID Gold assay
(Figure 7).
Figure 3. Schematic illustration of the three experimental strategies used for determining whether exposure to mitomycin C (MMC)
induces trafficking of Pgp to the plasma membrane in hCMEC/D3-Pgp-EGFP cells.
doi:10.1371/journal.pone.0088154.g003
Figure 4. Mitomycin C induced Pgp-EGFP trafficking in hCMEC/D3-MDR1-EGFP (doxycycline-on) cells. A representative experiment is
shown. hCMEC/D3-MDR1-EGFP (doxycycline-on) cells were pretreated with 1 mM MMC for 1 h and cell nuclei of living cells were stained with
bisbenzimide H (blue) (scale bars = 30 mm). After 1 h of MMC exposure, fluorescence images were taken every 3.6 min for another 1 h in the presence
of MMC. Trafficking events of Pgp-EGFP fusion protein are labeled (arrows). Within 15 min after onset of confocal microscopic analysis (i.e., about
75 min after onset of MMC exposure), we observed that Pgp-EGFP started to traffick from intracellular compartments to the membrane. See Movie S1
illustrating the whole period between 60 min and 139.2 min in fast motion.
doi:10.1371/journal.pone.0088154.g004
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Functional analysis of Pgp trafficking by the calcein AM
extrusion assay
In the calcein AM extrusion assay, we studied the effect of
MMC (1 mM) following 20 h of 4 h exposure with MMC
(Figure 2D). MMC exposure significantly decreased intracellular
calcein accumulation, indicating an increased Pgp functionality,
which could be completely counteracted by tariquidar, thus
confirming the results from the two other accumulation assays.
However, the effect size resulting from MMC exposure (,10%) in
the calcein-AM assay was much smaller compared to the other
two assays. In an additional experiment illustrated in Figure S3, we
determined the effect of MMC on the transport rate in the calcein
AM extrusion assay. Furthermore, we examined whether the
concentration of calcein AM had an influence of the effect of
MMC. At all concentrations of calcein AM studied, MMC caused
a small (7–11%) but statistically significant decrease in intracellular
calcein, indicating enhanced efflux of calcein AM. The effect of
MMC was completely counteracted by tariquidar in all experi-
ments shown in Figure S3.
Role of lipid rafts in the temporal disconnect between
Pgp trafficking and increased Pgp function
These data with three different accumulation assays indicated
that MMC exposure increased the functional expression of Pgp-
EGFP fusion protein when the assays were performed 20 h after
4 h of MMC exposure. However, no significant decrease in
Rho123 or eFluxx-ID Gold accumulation was observed when the
experiments were performed directly after 2 h of MMC exposure
or at 4 and 8 hrs following 4 h of MMC exposure (Figure 6B,
Figure 7).
This temporal disconnect between the Pgp trafficking seen
microscopically (Figure 4) and biochemically (Figure 5) and the
time to reach measurable alterations in Pgp function prompted us
to further address the association of Pgp-EGFP with the cell
membrane upon treatment of hCMEC/D3-MDR1-EGFP cells
with MMC. As shown before (Figure 4 and Movie S1), 2 h of
MMC treatment leads to the assembly of Pgp in punctuate
structures at the cell surface. We asked therefore whether these
structures are compatible with an association of Pgp with DRMs.
For this purpose the cells were biotinylated followed by Lubrol
DRM isolation and Western blotting. Figure 8 shows Pgp in the
DRM as well as in the Lubrol-soluble fractions. After 2 h of MMC
treatment the proportion of Pgp-EGFP protein in the DRM
fraction increased by more than 2.5-fold as compared to the
control sample (Figure 8B;D). At the same time its proportion in
non-DRM or Lubrol-soluble fraction decreased by a similar ratio
(Figure 8A;C). Interestingly, the level of Pgp in the DRM fraction
decreased after 24 h of MMC treatment with concomitant
increase in its proportion in the Lubrol-soluble fraction
(Figure 8). The shift of Pgp from the DRM fraction to the
detergent-soluble fraction is associated with an increase in the
Figure 5. Treatment with mitomycin C (MMC) increases Pgp-EGFP fusion protein at the cell surface. (A) hCMEC/D3-MDR1-EGFP
(doxycycline-on) cells were treated with MMC (1 mM) for 2 or 4 h and analyzed at the end of the 2 h-exposure period or 20 h after the 4 h-exposure
period. Western blot analyses of cell surface proteins isolated via EZ-Link Sulfo-NHS-SS-Biotin-Neutravidin assay revealed an obvious increase of Pgp-
EGFP abundance at the cell surface after MMC exposure, whereas no effect on intracellular Pgp was seen. One representative result of six
independent experiments is shown. In (B), Pgp-EGFP bands of the cell surface were analyzed densitometrically and Pgp signals were normalized
relative to the coomassie-stained portion of the gel. Data variability is shown as 6 SEM of six experiments; significant differences of treated vs.
untreated samples are indicated by asterisk (P,0.05). (C, D) No significant induction of Pgp-EGFP fusion protein was measured in whole cell lysates at
the same exposure conditions used in (A). Respective P values in D were 0.5502 (2 h MMC) and 0.2534 (24 h MMC). Pgp-EGFP bands were analyzed
densitometrically and Pgp signals were normalized on actin. Data variability is shown as 6 SEM of three experiments.
doi:10.1371/journal.pone.0088154.g005
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functionality of Pgp as assessed by Rho-123 efflux (Figure 6B and
Figure 8).
For direct proof that the temporal disconnect between the
trafficking and the time to reach maximum alterations in Pgp
function was due to the association of Pgp with DRMs, we
disrupted lipid rafts by specifically depleting cholesterol of
hCMEC/D3-MDR1-EGFP cells with MbCD. Treatments of
these cells with MMC for 2 h led to a significant increase of
functional activity of Pgp (Figure 6B). This was correlated with an
increase of Pgp in the detergent soluble fraction and a decrease of
Pgp in the DRM fraction (see inset in Figure 6B).
Discussion
In order to study whether Pgp trafficking can be induced in
human brain capillary endothelial cells that form the BBB, we
transfected hCMEC/D3 cells with a tetracycline-inducible
MDR1-EGFP fusion plasmid. MDR1-GFP constructs have been
previously used to study intracellular localization and trafficking of
Pgp in other cell types [7,9,25–29], but, to our knowledge, a
tetracycline regulatory system to inducibly control Pgp expression
has not been previously described. As shown here, Pgp expression
can be very effectively controlled in this system, providing an ideal
environment in which cellular trafficking of the protein and
interactions with a variety of intracellular targets can be studied.
We can not rule out that the massive overexpression of the fusion
protein changes the physiology of the cells or the localization and
trafficking of Pgp, but cell phenotype and viability were not
affected, making these transfected cells a useful tool for the aims of
the present study.
As known from previous reports [13,30,18], hCMEC/D3 cells
express endogenous Pgp (and other efflux transporters) but
expression of Pgp is lower in hCMEC/D3 cells than in human
brain microvessels, although Pgp remains functional as shown by
the Rho123 uptake assay [16,18]. Compared to wild type cells,
Rho123 accumulation was significantly decreased in the doxycy-
Figure 6. Effect of mitomycin C (MMC) on Pgp-EGFP function-
ality studied with the Rho123 uptake assay. MMC significantly
increased the functionality of Pgp-EGFP fusion protein. ‘‘A’’: hCMEC/D3-
Pgp-EGFP (doxycycline-off/-on) cells were treated with MMC in Opti-
MEM medium (0.1 mM, 1 mM, 10 mM, 50 mM and 100 mM) for 4 hours
after which Opti-MEM medium was replaced by complete medium
again. Control cells were treated with Opti-MEM medium. After 23 h the
cells were incubated with 10 mM Rho123 for 1 h and intracellular
accumulation was measured, resulting in a dose-dependent increase in
Pgp-EGFP functionality. Experiments were performed in triplicates and
values are shown as mean 6 SEM. Significant effects of MMC during
doxycycline-off conditions are indicated by circles, while significant
effects of MMC during doxycycline-on conditions are indicated by
rhombs (P,0.05). Significant differences between doxycycline-on and –
off conditions are indicated by asterisk (P,0.05). ‘‘B’’ shows data (shown
in percent control) in which rhodamine uptake was measured directly
after 2 h of MMC (1 mM) exposure or at 4, 8, and 20 hrs following 4 h of
MMC (1 mM) exposure in hCMEC/D3-Pgp-EGFP (doxycyline-on) cells,
indicating a lack of MMC exposure on Pgp function in the 2, 8 and 12,
but not the 24 h experiment. The 24 h experiment was also performed
with 10 mM MMC, resulting in similar results (not illustrated). However,
when lipid rafts were disrupted by MbCD, MMC (1 mM) exposure for 2 h
significantly increased the functionality of Pgp-EGFP fusion protein,
which is illustrated by the right columns in ‘‘B’’. As shown in the inset,
this was correlated with a decrease of Pgp in the DRM fraction and an
increase of Pgp in the detergent soluble fraction. Significant differences
between controls and MMC-treated cells are indicated by asterisk
(P,0.05).
doi:10.1371/journal.pone.0088154.g006
Figure 7. Effect of mitomycin C (MMC) on Pgp-EGFP function-
ality studied with the eFluxx-ID Gold assay in the absence and
presence of the Pgp inhibitor tariquidar (TQ; 0.5 mM). The figure
shows data in which eFluxx-ID Gold uptake was measured directly after
2 h of MMC (1 mM) exposure or at 8 and 20 hrs following 4 h of MMC
(1 mM) exposure in hCMEC/D3-Pgp-EGFP (doxycyline-on) cells, indicat-
ing a lack of MMC exposure on Pgp function in the 2 and 12 h, but not
the 24 h experiment. Experiments were performed in triplicates and
values are shown as mean 6 SEM. Significant differences between
control or MMC exposure with tariquidar vs. exposure without
tariquidar are indicated by asterisk (P,0.001) while significant
difference between MMC exposure (without tariquidar) and control is
indicated by rhomb (P= 0.0353).
doi:10.1371/journal.pone.0088154.g007
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cline-induced hCMEC/D3-MDR1-EGFP cells, an effect that
could be blocked by tariquidar. This observation indicates that the
cells were expressing the Pgp-EGFP protein in a functional form
on the cell surface, but the extent of this increase in Pgp
functionality was smaller than would have been expected from the
large (,15fold) increase in Pgp expression in the transfected cells.
This, however, was a consequence of the fact that most of the
EGFP-tagged Pgp was localized intracellularly in hCMEC/D3
cells, rendering the transfected cells a valuable tool to study
trafficking of Pgp from intracellular pools to the cell membrane.
Newly synthesized Pgp can be delivered to the plasma
membrane in different ways [6]. The constitutive pathway involves
membrane protein incorporation into transport vesicles which
move directly to the plasma membrane along the cytoskeleton
[26]. The second pathway is via an intracellular endosomal system
in which protein-containing vesicles are transported to endosomal
compartments to form an intracellular pool, followed by further
transport to the plasma membrane [6]. For Pgp trafficking
observed in the present study, the second pathway is relevant,
although we do not know yet which endosomal compartment is
involved.
For inducing Pgp trafficking in hCMEC/D3 cells, we used
MMC, which has previously been reported to induce Pgp
trafficking in rat hepatoma (H4IIE) and MDR1-GFP transfected
canine kidney (MDCK) cells [7]. The latter study showed that 4 h
exposure to subtoxic concentrations of MMC induces an increase
in plasma membrane expression and function of Pgp at about 6–
12 h after exposure without changing total cellular Pgp. In
contrast to various other chemotherapeutic agents, MMC is not a
substrate, or at best a very poor substrate, for Pgp and does not
induce MDR1 mRNA [31], so that Pgp trafficking might be the
only way by which the cell can protect itself against this toxic
compound. However, the mechanisms by which MMC induces
Pgp trafficking are not known. In the present study, MMC was
shown to induce Pgp trafficking in MDR1-EGFP transfected
hCMEC/D3 cells, which, to our knowledge, is the first direct
evidence that drug-induced Pgp trafficking occurs in brain
capillary endothelial cells. Pgp trafficking was unequivocally
demonstrated by using confocal laser scanning microscopy after
exposure to MMC. Furthermore, similar to the findings of Maitra
et al. [7] in other cell types, MMC significantly increased
membrane-associated Pgp (but not total cellular Pgp) and
increased Pgp functionality as demonstrated by decreased
Figure 8. Increased Pgp function (as observed in the uptake assays; see Figures 2, 6, and 7) is associated with the transition of Pgp
from detergent (Lubrol) resistant membrane (DRM) domains to detergent soluble membrane domains. Doxycycline-induced hCMEC/
D3-MDR1-EGFP cells were treated with MMC (1 mM) for 2 or 4 h and analyzed at the end of the 2 h-exposure period or 20 h after the 4 h-exposure
period. Cell surface proteins were biotinylated with EZ-Link Sulfo-NHS-SS-Biotin. After solubilisation of these cells with 1% (w/v) of Lubrol WX, the
lysates were centrifuged at 100,0006 g for 45 min at 4uC. The DRMs (pellets) resuspended in 0.5 (w/v) DOC and 0.5% (w/v) Triton X-100 and the
soluble fractions (supernatant) were subjected to Neutravidin beads to isolate cell surface proteins. These were then analyzed by Western blotting
using antibodies against Pgp. The protein bands were analyzed by scanning densitometry. In ‘‘A’’ and ‘‘B’’, Pgp bands in DRMs and supernatant are
presented as percentage of the control in one representative experiment. Data in ‘‘C’’ and ‘‘D’’ are shown as means 6 SEM of three experiments.
Asterisks denote values that significantly differed (P,0.05).
doi:10.1371/journal.pone.0088154.g008
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Rho123, eFluxx-ID Gold, and calcein accumulation. The most
marked effect of MMC exposure was obtained with the relatively
new eFluxx-ID Gold assay, in which only viable cells are analyzed
by flow cytometry [19,20]. These data demonstrate for the first
time that endothelial cells that form the human BBB respond with
Pgp trafficking to exposure with a potentially toxic compound.
Cellular uptake of the fluorescent Pgp substrates Rho123 and
calcein-AM has previously been used to measure the functionality
of Pgp in hCMEC/D3 cells [13,16]. By using these assays with
and without inhibitors of Pgp, multidrug resistance associated
proteins (MRPs) and breast cancer resistance protein (BCRP),
Rho123 was more sensitive and selective to demonstrate Pgp
functionality in these cells than calcein-AM [13], which is
supported by the present experiments with tariquidar and MMC
in transfected hCMEC/D3 cells.
While Pgp trafficking occurred relatively rapidly after exposure
to MMC, it took more than 12 h before a significant decrease in
Rho123 or eFluxx-ID Gold uptake was determined, indicating a
temporal disconnect between the trafficking and the time to reach
a significant increase in Pgp function. This temporal discrepancy
between the confocal microscopic and Western blot findings and
Pgp substrate uptake measurements in the present MMC
experiments suggests that the bulk of Pgp is transported and
clustered in membrane domains and this type of Pgp assembly is
associated with a decrease in Pgp function, whereby the release of
Pgp from these domains occurs only slowly. This hypothesis is
supported by the localization pattern and association of Pgp with
DRMs or lipid rafts [11] and the increased functionality of Pgp
following disruption of lipid rafts by MbCD. The fact that no
comparable trafficking of Pgp-EGFP to the membrane was
observed with confocal microscopy under control conditions (i.e.,
in the absence of MMC) can be explained by previous studies in
MDR1-EGFP transfected HeLa cells, which demonstrated that
12–48 h are required before Pgp-EGFP is transported to the
plasma membrane [9], i.e., much longer than observed in this
study with MMC.
Drug-induced trafficking of Pgp at the BBB has previously been
suggested by Ott et al. [32] by studying effects of St. John’s Wort
(SJW) and SJW constituents on Pgp transport activity in porcine
brain capillary endothelial cells and freshly isolated brain
capillaries from pigs. The SJW constituent quercetin enhanced
Pgp transport activity (as indicated by calcein-AM uptake), which
could be blocked by brefeldin A, an inhibitor of vesicular
trafficking between the endoplasmatic reticulum and the Golgi
apparatus [32]. Based on this observation, Ott et al. [32] proposed
that the increase in Pgp activity by quercetin was likely due to
trafficking and membrane insertion of sub-apical vesicles contain-
ing transporter protein, but no direct evidence for this hypothesis
was provided. Likewise, Hartz et al. [33] suggested that protein
kinase C (PKC) may influence Pgp trafficking in brain capillary
endothelial cells, stimulating retrieval from the plasma membrane
into a vesicular compartment, as has been demonstrated for Pgp in
hepatocytes [34], but, again, no direct evidence has been provided.
A recent study by McCaffrey et al. [11] demonstrated induction of
Pgp trafficking at the BBB by peripheral inflammatory pain in rats,
and indicated that this stimulus promotes a dynamic redistribution
between membrane domains of Pgp and caveolin-1.
At the BBB, Pgp is mainly localized in caveolin-1/flotillin-2
positive caveolar microdomains (known as lipid rafts) and its
activity can be modulated by interaction with caveolin-1 [35]. This
localization in microdomains most likely explains the clustered
formation of Pgp-EGFP observed in our study and a more recent
study by Huber et al. [20] in hCMEC/D3 cells. The mechanism
by which the Pgp activity is induced by MMC is not entirely clear.
However, our data reveal an MMC-induced time-dependent
punctuate pattern of Pgp at the cell surface. This pattern is
compatible with the association of Pgp with Lubrol DRMs.
Interestingly, reduced levels of Pgp in Lubrol DRMs and its
concomitant increase in the Lubrol-soluble fraction are associated
with increased function, and such increased function is also
observed at earlier time points when disrupting lipid rafts by
MbCD.
Certainly, it would be tempting to study the effects of other
compounds, including antiepileptic drugs [36] and neurotoxic
compounds such as glutamate, on Pgp trafficking in MDR1-
EGFP-transfected hCMEC/D3 cells. In addition to better
understanding how Pgp at the BBB responds to drug exposure,
manipulation of Pgp trafficking, e.g., by preventing its release from
subcellular stores, may present a novel, reversible means of
modulating drug delivery to the brain.
Supporting Information
Figure S1 Concentration-dependent increase in Pgp
functionality by doxycycline in hCMEC/D3-MDR1-
EGFP cells. The Rho123 uptake assay was used for determining
Pgp functionality. Data are shown as means 6 SEM of three
experiments per doxycycline concentration. Asterisks denote
values that significantly differ from Rho123 uptake in the absence
of doxycycline (P,0.01).
(TIF)
Figure S2 Efflux of rhodamine 123 (Rho123) in doxycy-
cline-induced hCMEC/D3-MDR1-EGFP cells in the
absence (‘‘untreated’’) or presence of the Pgp inhibitor
tariquidar (TQ; 0.5 mM). ‘‘A’’: Cells were preloaded with
Rho123 at 4uC (to inhibit any Pgp-mediated efflux) and then the
decay of intracellular fluorescence was measured at 37uC at 15, 30
and 60 min following preloading. Data are shown as means 6
SEM (n= 3). The Rho123 efflux rate as calculated from these data
is shown in ‘‘B’’. Significant differences between untreated and
tariquidar-treated cells is indicated by asterisk (P,0.05).
(TIF)
Figure S3 Determination of transport rates and effect of
MMC in the calcein AM extrusion assay in the absence
or presence of tariquidar. Efflux of calcein AM was indirectly
measured by determining the intracellular concentration of the
fluorescent calcein at different concentrations (0.25, 0.5, 1, and
2 mM) of calcein AM. The transport rate was calculated in calcein
fluorescence per sec per mg protein. In the MMC experiments,
transport was measured 20 h after a 4 h exposure with 1 mM
MMC. Although the effect size was small, MMC significantly
decreased intracellular calcein at all concentrations of calcein AM
(indicated by rhomb; P,0.05), demonstrating enhanced calcein
AM efflux. Tariquidar (TQ; 0.5 mM) completely counteracted this
effect of MMC (indicated by asterisk; P,0.001). Data are shown
as means 6 SEM (n= 3).
(TIF)
Movie S1 Mitomycin C induced Pgp-EGFP trafficking in
hCMEC/D3-MDR1-EGFP (doxycycline-on) cells. The
movie shows a period of 79.2 min in fast motion following 1 h
of MMC exposure (see Figure 4 for single images and more
details). In the endothelial cell in the centre of the images, we
observed that Pgp-EGFP trafficked from intracellular compart-
ments to the membrane; this started within 15 min after onset of
confocal microscopic analysis (i.e., about 75 min after onset of
MMC exposure).
(ZIP)
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Movie S2 Lack of obvious Pgp-EGFP trafficking in
hCMEC/D3-MDR1-EGFP (doxycycline-on) cells in the
absence of mitomycin C. The same time frame as used in
Movie S1 is used.
(ZIP)
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